Sandbox2

Revision as of 14:26, 19 March 2014 by Alonso Alvarado (talk | contribs)
Jump to navigation Jump to search

|

Overview

Wolff-Parkinson-White syndrome (WPW) is a syndrome of pre-excitation of the ventricles of the heart due to an accessory pathway known as the Bundle of Kent. The diagnosis is made when a patient with pre-existing WPW patern in the ECG developes an arrythmia which involves an accesory pathway. The treatment is focused on recovering sinus rythm. Atrial Fibrillation in a patient with WPW is lifethretening and should be managed urgently.

Causes

Life Threatening Causes

Life-threatening causes include conditions which result in death or permanent disability within 24 hours if left untreated. Wolff-Parkinson-White syndrome can be a life-threatening condition and must be treated as such irrespective of the underlying cause.

Common Causes

WPW is a congenic disease

Diagnosis

Shown below is an algorithm summarizing the initial aproach to Wolff-Parkinson-White syndrome according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]

AVRT: AV reentrant tachycardia

 
 
 
 
 
 
 
 
 
 
 
 
Characterize the symptoms:
❑ Asymptomatic PalpitationsDyspnea
Fatigue Chest discomfort Lightheadedness
Syncope Polyuria

Characterize the timing of the symptoms:
❑ Onset
❑ Duration
❑ Frequency

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

❑ Examine the patient

❑ Monitor the blood pressure
❑ Monitor the heart rate

❑ Order and monitor the ECG
❑ Assess and support ABC
❑ Give oxygen if needed
❑ Treat reversible causes if identified

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orthodromic AVRT

The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of WPW

❑ Narrow QRS complexes
❑ Ventricular rate between 150-250 bpm (or more) usually regular
❑ Short PR interval less than one half of the tachycardia RR interval

 
 
 
 
 
Antidromic AVRT

The impulse travels from the atrium to the ventricle through theaccesory pathway and from the ventricle to the atrium through the AV node. Less than 10% of WPW

❑ Wide QRS complexes
❑ Ventricular rate between 150-250 bpm (or more) usually regular
❑ Short PR interval more than one half of the tachycardia RR interval

 
 
 

Managment

Initial Management

Shown below is an algorithm summarizing the initial aproach to Wolff-Parkinson-White syndrome according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]

 
 
 
 
 
 
 
 
 
 
 
 

❑ Determine blood pressure
❑ Determine heart rate

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stable patient
 
 
 
 
 
Unstable patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess the ECG
 
 
 
 
 
❑ Urgent electrical cardioversion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orthodromic AVRT
 
 
 
 
 
Antidromic AVRT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment.[2][3][4]

❑ Use Valsalva maneuvers

If not effective initiate IV AV nodal blocking agent

❑ Administer Adenosine

If not effective

❑ Administer Verapamil

If not effective

❑ Administer Procainamide

 
 
 
 
 
Treatment.

❑ Administration of Procainamide, Flecainide or Ibutilide is the prefered treatment
Adenosine should be used with caution because may produce AF

 
 
 

Wolff-Parkinson-White syndrome with Atrial fibrillation

Shown below is an algorithm summarizing the managment of Wolff-Parkinson-White syndromewith Atrial fibrillation according to the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation.[5]

 
 
 
 
 
 
 
 
 

❑ Control ventricular response
❑ If possible: terminate AF
❑ If possible: catheter ablation of the accesory pathway (class I, level of evidence B)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stable patient
 
 
 
 
 
 
 
Unstable patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

❑ Urgent electric cardioversion (class I, level of evidence B)
❑ Is reasonable to use Flecainide or electrical cardioversion for very rapid ventricular response (class IIa, level of evidence B)

 
 
 

References

  1. 1.0 1.1 "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.
  2. Mehta, D.; Wafa, S.; Ward, DE.; Camm, AJ. (1988). "Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia". Lancet. 1 (8596): 1181–5. PMID 2897005. Unknown parameter |month= ignored (help)
  3. Jackman, WM.; Friday, KJ.; Fitzgerald, DM.; Yeung-Lai-Wah, JA.; Lazzara, R. (1988). "Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia". Am J Cardiol. 62 (19): 8L–19L. PMID 3059792. Unknown parameter |month= ignored (help)
  4. Sung, RJ.; Elser, B.; McAllister, RG. (1980). "Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations". Ann Intern Med. 93 (5): 682–9. PMID 7212475. Unknown parameter |month= ignored (help)
  5. Fuster, V.; Rydén, LE.; Cannom, DS.; Crijns, HJ.; Curtis, AB.; Ellenbogen, KA.; Halperin, JL.; Le Heuzey, JY.; Kay, GN. (2006). "ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (7): e257–354. doi:10.1161/CIRCULATIONAHA.106.177292. PMID 16908781. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources